A detailed review of elastic fiber biology, the mechanisms by which CF pathophysiology disrupts elastic fiber integrity, the downstream structural and functional consequences, and potential therapeutic avenues targeting elastic fiber preservation or restoration are provided.
Abstract
Cystic fibrosis (CF) is a multisystem autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, affecting approximately 100,000 individuals worldwide. While the primary pathology of CF has historically been framed around airway mucus obstruction, chronic infection, and neutrophilic inflammation, emerging evidence points to profound remodeling of the extracellular matrix (ECM), and elastic fibers in particular, as central contributors to disease progression. Elastic fibers, composed of an elastin core surrounded by a fibrillin-rich microfibril scaffold, provide tissues with the resilience and recoil necessary for repetitive mechanical deformation, properties especially critical in the lung, large airways, skin, and vasculature. In CF, a convergence of proteolytic imbalance, oxidative stress, inflammatory mediators, and impaired CFTR-dependent ion transport conspires to degrade and destabilize these fibers at multiple anatomical sites. The consequences include progressive airflow obstruction, bronchiectasis, emphysema-like changes, impaired mucociliary clearance, and systemic connective tissue vulnerabilities. This paper provides a detailed review of elastic fiber biology, the mechanisms by which CF pathophysiology disrupts elastic fiber integrity, the downstream structural and functional consequences, and potential therapeutic avenues targeting elastic fiber preservation or restoration.
Insights from experimental models of pulmonary fibrosis and translational research have significantly advanced understanding of these processes and are reviewed in this article, together with current therapeutic advances and future directions.
Nazanin Nazemi, B. Crestani, D. Helou et al.· European Respiratory Journal· 0 citations
Pediatric CF is associated with selective alterations in circulating type 3 and regulatory immune responses, characterized by increased IL-22-producing lymphocyte populations, reduced plasma IL-17 A concentrations, and increased numbers of CD3⁺IL-10⁺ cells.
Tugba Nur Gur, Z. B. Azizoğlu, Yesim Haliloğlu et al.· Molecular Biology Reports· 0 citations
Pulmonary fibrosis (PF) encompasses a spectrum of progressive and irreversible interstitial lung diseases characterized by a notably poor prognosis. The principal pathological features of PF include recurrent injury to the alveolar epithelium, aberrant accumulation of extracellular matrix (ECM) components, and disrupti...
Yu-Jie Yang, Sen-Yuan Liu, Shang-Xuan Wang et al.· Pharmacological Research· 0 citations
Pulmonary fibrosis is a fatal interstitial lung disease characterized by excessive fibroblast proliferation and aberrant deposition of extracellular matrix (ECM), ultimately leading to structural lung destruction and respiratory failure. Neutrophils, as key effector cells of innate immunity, have been increasingly reco...
Zu-Ming Chen, Jin-Yu Tang, Zi-Han Wang et al.· International Immunopharmaco...· 0 citations
The core mechanisms of how inter‐organelle network disruptions drive fibrosis are clarified, with the goal of identifying critical organelle nodes to disrupt pathogenic metabolic reprogramming and ultimately provide a rationale for developing new treatments.
Yi-Ning Zhang, Ling Teng, Li-Ming Gong et al.· Cell Biochemistry and Functi...· 0 citations
The context-dependent role of sirtuin 3 (SIRT3), a mitochondrial nicotinamide adenine dinucleotide (NAD⁺)-dependent deacetylase, in linking mitochondrial homeostasis, oxidative stress, metabolic adaptation, and profibrotic signaling is discussed.
Hui Xie, Xue-Jie Zheng, Xiu-Ying Wang et al.· Molecular Biomedicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.